A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial
if the combination of sulindac and erlotinib causes a significant regression of duodenal and
colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP (AFAP)
patients.